Prestige Consumer Healthcare (PBH)
NYSE:PBH
Want to see PBH full AI Analyst Report?
PBH Stock Chart & Stats
$58.13
-$0.15(-0.20%)
At close: 4:00 PM EST
$58.13
-$0.15(-0.20%)
Day’s Range― - ―
52-Week Range$51.24 - $89.37
Previous CloseN/A
Volume57.25K
Average Volume (3M)456.76K
Market Cap
$2.65B
Enterprise Value$3.67B
Total Cash (Recent Filing)$62.37M
Total Debt (Recent Filing)$1.08B
Price to Earnings (P/E)15.8
Beta0.35
Next Earnings
Apr 30, 2026EPS Estimate
1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding47,318,730
10 Day Avg. Volume504,397
30 Day Avg. Volume456,760
Financial Highlights & Ratios
PEG Ratio7.62
Price to Book (P/B)2.33
Price to Sales (P/S)3.76
P/FCF Ratio17.56
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue3.32
Enterprise Value/Gross Profit5.89
Enterprise Value/Ebitda10.83
Forecast
1Y Price Target
$82.20Price Target Upside41.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)4.81
Revenue Forecast (FY)$1.15B
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyAnalyst notes the acquisition of Breathe Right and other over-the-counter brands should be accretive to earnings and broaden the company's presence in nasal care and related consumer health categories.
Capital Deployment FlexibilityAnalyst points to strong free cash flow and available buyback capacity as enablers for opportunistic share repurchases, accretive acquisitions, and debt reduction.
Margin ExpansionAnalyst highlights that the acquired portfolio carries substantially higher gross and adjusted EBITDA margins than the company's existing brands, which should lift overall company margins.
Bears Say
Guidance And Sales Recovery RiskAnalyst observes management narrowed company guidance toward the low end of prior ranges and cautions that long customer purchase cycles and tighter retailer inventory management make a quick sales rebound unlikely, creating downside risk to growth expectations.
Leverage And FinancingAnalyst warns the planned funding mix of cash plus a new term loan will increase leverage and raise financial risk after the acquisition closes.
Retail Demand And InventoryAnalyst notes inventory de-stocking at certain retail channels and softer category demand have reduced orders and pressured sales momentum.
Prestige Consumer Healthcare News
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $51.24 and its highest was $89.37 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $2.65B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Apr 30, 2026 which is today.
How were Prestige Consumer Healthcare’s earnings last quarter?
Currently, no data Available
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare pays a Notavailable dividend of $0.475 which represents an annual dividend yield of N/A. See more information on Prestige Consumer Healthcare dividends here
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 1.39.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 47,318,730 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in PBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prestige Consumer Healthcare Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$82.20 (41.41% Upside)
$82.20 (41.41% Upside)
Blogger Sentiment
Bullish
PBH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 822.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $65.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.37%
12-Months-Change
Fundamentals
Return on Equity
10.16%
Trailing 12-Months
Asset Growth
4.96%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
PBH Company Deck
PBH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear operational and financial strengths — notably strong free cash flow (+~13% YTD), margin expansion (first nine months gross margin +50 bps and Q4 guide to ~57%), strategic acquisition (Pillar Five) to remedy long-standing Clear Eyes supply issues, and opportunistic buybacks — against persistent near-term headwinds driven by Clear Eyes supply constraints, category softness in analgesics/cough & cold/lice, a $10M supplier loan write-off, and volatile retailer ordering patterns. Management projects continued sequential supply improvements and maintained full-year free cash flow and narrowed EPS and revenue guidance, indicating confidence in financial resilience while acknowledging ongoing execution and demand uncertainties.View all PBH earnings summariesPBH Stock 12 Month Forecast
Average Price Target
$82.20
▲(41.41% Upside)
Technical Analysis
Cardinal Health
―
Henry Schein
―
McKesson
―
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
1.34% Insiders
45.64% Mutual Funds
4.14% Other Institutional Investors
21.03% Public Companies and
Individual Investors